According to the clinical trial studies such as CD19/20 bispecific NbCAR-T cells against B cell lymphoma (NCT03881761) and BCMA-NbCAR-T cells (NCT03664661) and LCAR-B38M-NbCAR-T cells against multiple myeloma, it seems that NbCAR-T cells targeting blood cancers have the more likelihood to reach FDA approval. The gene discussed is CD19; the disease is plasma cell myeloma.